S12 Ep42: Radioligand Therapy Advances Represent the Future of mCRPC Treatment: With Daniel P. Petrylak, MD

OncLive® On Air - A podcast by OncLive® On Air

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

Daniel P. Petrylak, MD, discusses the role of Lutetium Lu 177 vipivotide tetraxetan in metastatic castration-resistant prostate cancer.